Rapport Therapeutics (RAPP) Cash from Investing Activities (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Cash from Investing Activities for 4 consecutive years, with $37.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 80.41% year-over-year to $37.9 million; the TTM figure through Mar 2026 stood at -$170.6 million (down 59.13% YoY), while the FY2025 annual figure was -$187.5 million, down 10.19% from the prior year.
• Cash from Investing Activities advanced to $37.9 million in Q1 2026 per RAPP's latest filing, from -$174.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $37.9 million in Q1 2026 and bottomed at -$174.3 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$36.2 million across 4 years, with a median of -$41.9 million in 2024.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 101901.92% — and 2025, when it surged 150.16%.
• Rapport Therapeutics' Cash from Investing Activities stood at -$78.7 million in 2023, then jumped by 140.59% to $31.9 million in 2024, then slumped by 645.96% to -$174.3 million in 2025, then soared by 121.76% to $37.9 million in 2026.
• Business Quant data shows RAPP's Cash from Investing Activities at $37.9 million in Q1 2026, -$174.3 million in Q4 2025, and -$56.8 million in Q3 2025.